Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* =/\> 18 years of age~* Prescribed Continuous Venovenous Hemodialysis (CVVHD) as determined by the primary physician~* Prescribed daptomycin as determined by the primary physician~* Informed consent granted~Exclusion Criteria:~* \< 18 years of age~* Allergy to daptomycin~* Patients being primarily treated with daptomycin for diagnosis of osteomyelitis, meningitis, or pneumonia without adequate concomitant use of other more effective antimicrobial agents as daptomycin is not indicated for primary treatment of these types of infections~* Inability to complete 48 hours of Continuous Venovenous Hemodialysis (CVVHD)~* Concurrent use of other extracorporeal therapies such as Extracorporeal Membrane Oxygenation (ECMO) or plasmapheresis and intermittent hemodialysis~* Inability to obtain informed consent~* Pregnant and/or breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).